The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: A mythical truth

EPMA Journal

Volumn 1, Issue 1, 2010, Pages 46-55

  Baban, Babak ^a   Penberthy, W Todd ^b   Mozaffari, Mahmood S ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

IDO; Individual tolerance; Predictive diagnostic; Targeted treatment; Type 1 diabetes

Indexed keywords

ABATACEPT; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TH17 CELL; TREATMENT PLANNING; UPREGULATION;

EID: 85027947433     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0009-2     Document Type: Review

References (70)

1. Sugimoto H, Oda S, Otsuki T, et al. Crystal structure of human indoleamine 2, 3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA. 2006;103(8):2611-6.
2. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2, 3-dioxygenase-like protein found in humans and mice. Gene 2007;396(1):203-13.
3. Ball HJ, Yuasa HJ, Austin CJ, et al. Indoleamine 2, 3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol. 2009;41(3):467-71.
4. Metz R, Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(15):7082-7.
5. Hayashi T, Beck L, Rossetto C, et al. Inhibition of experimental asthma by indoleamine 2, 3-dioxygenase. J Clin Invest. 2004;114 (2):270-9.
6. Baban B, Chandler P, McCool D, et al. Indoleamine 2, 3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol. 2004;61(2):67-77.
7. Beutelspacher SC, Tan PH, McClure MO, et al. Expression of indoleamine 2, 3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am J Transplant. 2006;6 (6):1320-30.
8. Mohib K, Wang S, Guan Q, et al. Indoleamine 2, 3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2008;295(1):F226-34.
9. Chen Y, Guillemin GJ. Kynurenine Pathway Metabolites in Humans: Disease and Healthy States. Int J Tryptophan Res. 2009;2:1-19.
10. Littlejohn TK, Takikawa O, Truscott RJ, et al. Asp274 and his346 are essential for heme binding and catalytic function of human indoleamine 2, 3-dioxygenase. J Biol Chem. 2003;278(32):29525-31.
11. Johnson BA, Baban B, Mellor AL (2009) Targeting the immunoregulatory Indoleamine 2,3-dioxygenase pathway in Immunotherapy. Immunotherapy 1(4)
12. Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA. 1984;81(3):908-12.
13. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281 (5380):1191-3.
14. Müller A, Heseler K, Schmidt SK, et al. The missing link between indoleamine 2, 3-dioxygenase mediated antibacterial and immunoregulatory effects. J Cell Mol Med. 2009;13(6):1125-35.
15. Spekker K, Czesla M, Ince V, et al. Indoleamine 2, 3-dioxygenase is involved in defense against Neospora caninum in human and bovine cells. Infect Immun. 2009;77(10):4496-501.
16. Curti A, Trabanelli S, Salvestrini V, et al. The role of indoleamine 2, 3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009;113(11):2394-401.
17. Kaufmann SH. Immunity to intracellular bacteria. Annu Rev Immunol. 1993;11:129-63.
18. Yoshida R, Hayaishi O. Induction of pulmonary indoleamine 2, 3- dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci USA. 1978;75:3998-4000.
19. Däubener W, Spors B, Hucke C, et al. Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2, 3-dioxygenase. Infect Immun.2001;69:6527-31.
20. Mackler AM, Barber EM, Takikawa O, et al. Indoleamine 2, 3-dioxygenase is regulated by IFN-gamma in the mouse placenta during Listeria monocytogenes infection. J Immunol. 2003;170: 823-30.
21. Yoshida R, Urade Y, Tokuda M, et al. Induction of indoleamine 2, 3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci USA. 1979;76:4084-6.
22. Bonifazi P, Zelante T, D'Angelo C, De Luca A, Moretti S, Bozza S, et al. Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol. 2009;2(4):362-374. Epub 2009 May 6.
23. Zelante T, Fallarino F, Bistoni F, Puccetti P, Romani L. Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. Microbes Infect. 2009;11(1):133-141. Epub 2008 Oct 25.
24. Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9(10):1269-74.
25. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114(2):280-90. Erratum in: J Clin Invest 114(4):599.
26. Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312-9.
27. Gao YF, Peng RQ, Li J, et al. The paradoxical patterns of expression of indoleamine 2, 3-dioxygenase in colon cancer. J Transl Med. 2009;7:71.
28. Lee JR, Dalton RR, Messina JL, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest. 2003;83(10):1457-66.
29. Urakawa H, Nishida Y, Nakashima H et al (2009) Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis [Epub ahead of print]
30. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006;12 (4):1144-51.
31. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005;11(16):6030-9.
32. Takao M, Okamoto A, Nikaido T, et al. Increased synthesis of indoleamine-2, 3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep. 2007;17(6):1333-9.
33. Pan K, Wang H, Chen MS, et al. Expression and prognosis role of indoleamine 2, 3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134(11):1247-53.
34. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Inducing the tryptophan catabolic pathway, indoleamine 2, 3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 2009;114(24):5062-70.
35. Ingelsten M, Gustafsson K, Oltean M, et al. Is indoleamine 2, 3- dioxygenase important for graft acceptance in highly sensitized patients after combined auxiliary liver-kidney transplantation? Transplantation 2009;88(7):911-9.
36. Wang C, Tay SS, Tran GT et al Donor IL-4-treatment induces alternatively activated liver macrophages and IDO-expressing NK cells and promotes rat liver allograft acceptance. Transpl Immunol [Epub ahead of print]
37. Platten M, Ho PP, Youssef S, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005;310(5749):850-855. Erratum in: Science. 2006 Feb 17;311(5763):954.
38. Zhang Q, Shi S, Liu Y, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol. 2009;183(12):7787-98.
39. Zhu L, Ji F, Wang Y, et al. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol. 2006;177:8226-33.
40. Takakubo Y, Takagi M, Maeda K, et al. Distribution of myeloid dendritic cells and plasmacytoid dendritic cells in the synovial tissues of rheumatoid arthritis. J Rheumatol. 2008;35(10):1919-31.
41. Scott GN, DuHadaway J, Pigott E, et al. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol. 2009;182(12):7509-17.
42. Jalili RB, Forouzandeh F, Moeenrezakhanlou A, et al. Mouse pancreatic islets are resistant to indoleamine 2, 3 dioxygenaseinduced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function. Am J Pathol. 2009;174(1):196-205.
43. Fallarino F, Volpi C, Zelante T, et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol. 2009;183(10):6303-12.
44. Saxena V, Ondr JK, Magnusen AF, et al. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol. 2007;179(8):5041-53.
45. Ueno A, Cho S, Cheng L, et al. Transient upregulation of indoleamine 2, 3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes 2007;56(6):1686-93.
46. Brandacher G, Cakar F, Winkler C, et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int. 2007;71(1):60-7.
47. Penberthy WT. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab. 2007;8(3):245-66.
48. Swanson KA, Zheng Y, Heidler KM, et al. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2, 3-dioxygenase. Am J Respir Cell Mol Biol. 2004; 30:311-8.
49. Liu H, Liu L, Liu K, et al. Novel action of indoleamine 2, 3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med. 2006;173:566-72.
50. Liu H, Liu L, Liu K, et al. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2, 3-dioxygenasedependent immune suppression. J Immunol. 2009;183:1022-31.
51. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol. 2009;183(4):2475-83.
52. Nikolic T, Welzen-Coppens JM, Leenen PJ, et al. Plasmacytoid dendritic cells in autoimmune diabetes-potential tools for immunotherapy. Immunobiology 2009;214(9-10):791-9.
53. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449(7161):419-26.
54. Kadowaki N. The divergence and interplay between pDC and mDC in humans. Front Biosci. 2009;14:808-17.
55. Kadowaki N. Dendritic cells: a conductor of T cell differentiation. Allergol Int. 2007;56(3):193-9.
56. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8(1):74-80. Erratum in: Nat Rev Immunol. 2008 Feb;8(2):160
57. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135-43.
58. Pechhold K, Koczwara K. Immunomodulation of autoimmune diabetes by dendritic cells. Curr Diab Rep. 2008;8(2):107-13.
59. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 2002;297(5588):1867-70.
60. Fallarino F, Vacca C, Orabona C, et al. Functional expression of indoleamine 2, 3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol. 2002;14(1):65-8.
61. Baban B, Hansen AM, Chandler PR, et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol. 2005;17(7):909-19.
62. Jaehn PS, Zaenker KS, Schmitz J, et al. Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol. 2008;38 (7):1822-32.
63. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449(7161):419-26.
64. Grohmann U, Fallarino F, Bianchi R, et al. Tryptophan catabolism in nonobese diabetic mice. Adv Exp Med Biol. 2003; 527:47-54.
65. Fallarino F, Luca G, Calvitti M, et al. Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Exp Med. 2009;206(11):2511-26.
66. Li Q, Xu B, Michie SA, et al. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008;105(34):12439-44.
67. Ueda Y, Hagihara M, Okamoto A, et al. Frequencies of dendritic cells (myeloid DC and plasmacytoid DC) and their ratio reduced in pregnant women: comparison with umbilical cord blood and normal healthy adults. Hum Immunol. 2003;64(12):1144-51.
68. Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest. 2007;117(9):2570-82.
69. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5(12):1219-26.
70. Soumelis V, Liu YJ. From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol. 2006;36(9):2286-92.